The authors suggested that the efficacy of several pan-HER family inhibitors (afatinib, canertinib, dacomitinib, varlitinib, and neratinib) in lapatinib-resistant HER2+ breast cancer models was potentially dependent on their ability to inhibit HER4 activity. Here, ERBB2 is linked to breast cancer.